Present and future of adeno associated virus based gene therapy approaches

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 6, Issue 1, 2012, Pages 47-66

  Ortolano, Saida ^a   Spuch, Carlos ^a   Navarro, Carmen ^a  

^a UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

Author keywords

AAV; Capsid variants; Gene therapy; Lysosomal storage disorders; Monogenic diseases; Neurodegenerative diseases; Neuromuscular diseases; Self complemenary virus

Indexed keywords

ADENOVIRUS VECTOR; ALPHA 1 ANTITRYPSIN; ALPHA GLUCOSIDASE; ALPHA SARCOGLYCAN; BLOOD CLOTTING FACTOR 9; DYSTROPHIN; FC RECEPTOR; GAMMA SARCOGLYCAN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTAMATE DECARBOXYLASE; PEPTIDES AND PROTEINS; PROTEIN AADC; PROTEIN ASPA; PROTEIN CLN2; PROTEIN SERCA2A; PROTEIN SFLT01; TRANSMEMBRANE CONDUCTANCE REGULATOR; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; VISUAL PIGMENT;

3' UNTRANSLATED REGION; ALPHA 1 ANTITRYPSIN DEFICIENCY; BINDING AFFINITY; BLOOD BRAIN BARRIER; CELL MIGRATION; CENTRAL NERVOUS SYSTEM; CYSTIC FIBROSIS; DENSITY GRADIENT CENTRIFUGATION; DNA REPLICATION; DNA TRANSFECTION; DRUG PACKAGING; DUCHENNE MUSCULAR DYSTROPHY; GENE EXPRESSION; GENE REPLICATION; GLYCOGEN STORAGE DISEASE TYPE 2; HEART FAILURE; HEMOPHILIA B; HERPES SIMPLEX VIRUS; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; INFLAMMATORY DISEASE; INVERTED TERMINAL REPEAT; LEBER CONGENITAL AMAUROSIS; LIFE CYCLE; LIVER; MUSCULAR DYSTROPHY; MUTAGENESIS; NEURONAL CEROID LIPOFUSCINOSIS; NONHUMAN; OPEN READING FRAME; PARKINSON DISEASE; PATENT; PRIORITY JOURNAL; RECEPTOR BINDING; RETINA; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RHEUMATOID ARTHRITIS; SEROTYPE; SKELETAL MUSCLE; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRAL TROPISM; VIRION; VIRUS CAPSID; VIRUS MORPHOLOGY; VIRUS PARTICLE; VIRUS PURIFICATION; VISION;

ANIMALS; DEPENDOVIRUS; GENE THERAPY; GENETIC VECTORS; HUMANS; PATENTS AS TOPIC;

EID: 84856544895     PISSN: 18722148     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221412799015245     Document Type: Review

References (194)

1. Mingozzi F, High KA. Therapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges. Nat Rev Genet 2011; 12(5): 341-355.
2. Gaudet D, de Wal J, Tremblay K, Déry S, van Deventer S, Freidig A, et al. Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency. Atheroscler 2011; 11(1): 55-60.
3. Afione SA, Conrad CK, Kearns WG, Chunduru S, Adams R, Reynolds TC, et al. In vivo model of adeno-associated virus vector persistence and rescue. J Virol 1996; 70(5): 3235-3241.
4. Atchison RW, Casto BC, Hammon WM. Adenovirus-associated defective virus particles. Science 1965; 149: 754-6.
5. Mayor HD, Jamison RM, Jordan LE, Melnick JL. Structure and composition of a small particle prepared from a simian adenovirus. J Bacteriol 1965; 90(1): 235-242.
6. Kerr JR, Linden RM, Human dependovirus infection, in Kerr JR, Cotmore SF, Bloom ME, Linden RM, Parrish CR, editors Parvoviruses, Hodder Arnold, London, UK, 2006; 381-385.
7. Buning H, Perabo L, Coutelle O, Quadt-Humme S, Hallek M. Recent developments in adeno-associated virus vector technology. J Gene Med 2008; 10(7): 717-733.
8. Heilbronn R, Weger S. Viral vectors for gene transfer: Current status of gene therapeutics. Handb Exp Pharmacol 2010; (197): 143-170.
9. Daya S, Berns KI. Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev 2008; 21(4): 583-593.
10. Pereira DJ, Muzyczka N. The adeno-associated virus type 2 p40 promoter requires a proximal Sp1 interaction and a p19 CArG-like element to facilitate Rep transactivation. J Virol 1997; 71(6): 4300-9.
11. Summerford C, Samulski RJ. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 1998; 72(2): 1438-45.
12. Rabinowitz JE, Rolling F, Li C, Conrath H, Xiao W, Xiao X, et al. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 2002; 76(2): 791-801.
13. Blackburn SD, Steadman RA, Johnson FB. Attachment of adenoassociated virus type 3H to fibroblast growth factor receptor 1. Arch Virol 2006; 151(3): 617-23.
14. Kaludov N, Brown KE, Walters RW, Zabner J, Chiorini JA. Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity. J Virol 2001; 75(15): 6884-93.
15. Di Pasquale G, Chiorini JA. AAV transcytosis through barrier epithelia and endothelium. Mol Ther 2006; 13(3): 506-16.
16. Vandendriessche T, Thorrez L, Acosta-Sanchez A, Petrus I, Wang L, Ma L, et al. Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy. J Thromb Haemost 2007; 5(1): 16-24.
17. Di Pasquale G, Kaludov N, Agbandje-McKenna M, Chiorini JA. BAAV transcytosis requires an interaction with beta-1-4 linkedglucosamine and gp96. PLoS One 2010; 5(3): e9336.
18. Asokan A, Hamra JB, Govindasamy L, Agbandje-McKenna M, Samulski RJ. Adeno-associated virus type 2 contains an integrin alpha5beta1 binding domain essential for viral cell entry. J Virol 2006; 80(18): 8961-9.
19. Sanlioglu S, Benson P, Engelhardt JF. Loss of ATM function enhances recombinant adeno-associated virus transduction and integration through pathways similar to UV irradiation. Virology 2000; 268(1): 68-78.
20. den Hollander AI, Roepman R, Koenekoop RK, Cremers FP. Leber congenital amaurosis: Genes, proteins and disease mechanisms. Prog Retin Eye Res 2008; 27(4): 391-419.
21. Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 2008; 358(21): 2231-9.
22. Yan Z, Zak R, Zhang Y, Ding W, Godwin S, Munson K, et al. Distinct classes of proteasome-modulating agents cooperatively augment recombinant adeno-associated virus type 2 and type 5- mediated transduction from the apical surfaces of human airway epithelia. J Virol 2004; 78(6): 2863-74.
23. Kotin RM, Menninger JC, Ward DC, Berns KI. Mapping and direct visualization of a region-specific viral DNA integration site on chromosome 19q13-qter. Genomics 1991; 10(3): 831-4.
24. Kotin RM, Linden RM, Berns KI. Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination. Embo J 1992; 11(13): 5071-8.
25. Dutheil N, Shi F, Dupressoir T, Linden RM. Adeno-associated virus site-specifically integrates into a muscle-specific DNA region. Proc Natl Acad Sci USA 2000; 97(9): 4862-6.
26. Tan I, Ng CH, Lim L, Leung T. Phosphorylation of a novel myosin binding subunit of protein phosphatase 1 reveals a conserved mechanism in the regulation of actin cytoskeleton. J Biol Chem 2001; 276(24): 21209-16.
27. Redemann BE, Mendelson E, Carter BJ. Adeno-associated virus rep protein synthesis during productive infection. J Virol 1989; 63(2): 873-82.
28. Brister JR, Muzyczka N. Mechanism of Rep-mediated adenoassociated virus origin nicking. J Virol 2000; 74(17): 7762-71.
29. Linden RM, Winocour E, Berns KI. The recombination signals for adeno-associated virus site-specific integration. Proc Natl Acad Sci USA 1996; 93(15): 7966-72.
30. Linden RM, Ward P, Giraud C, Winocour E, Berns KI. Sitespecific integration by adeno-associated virus. Proc Natl Acad Sci U S A 1996; 93(21): 11288-94.
31. Weitzman MD, Kyostio SR, Kotin RM, Owens RA. Adenoassociated virus (AAV) Rep proteins mediate complex formation between AAV DNA and its integration site in human DNA. Proc Natl Acad Sci U S A 1994; 91(13): 5808-12.
32. Berns KI, Giraud C. Biology of adeno-associated virus. Curr Top Microbiol Immunol 1996; 218: 1-23.
33. Schnepp BC, Jensen RL, Chen CL, Johnson PR, Clark KR. Characterization of adeno-associated virus genomes isolated from human tissues. J Virol 2005; 79(23): 14793-803.
34. Blouin V, Brument N, Toublanc E, Raimbaud I, Moullier P, Salvetti A. Improving rAAV production and purification: towards the definition of a scaleable process. J Gene Med 2004; 6 (Suppl 1): S223-8.
35. Henckaerts E, Linden RM. Adeno-associated virus: A key to the human genome? Future Virol 2010; 5(5): 555-74.
36. Fischer A, Hacein-Bey-Abina S, Lagresle C, Garrigue A, Cavazana-Calvo M. Gene therapy of severe combined immunodeficiency disease: Proof of principle of efficiency and safety issues. Gene therapy, primary immunodeficiencies, retrovirus, lentivirus, genome. Bull Acad Natl Med 2005; 189(5): 779-85.
37. Dong, J., Frizzell, R. Methods and composition for the large scale production of recombinant adeno-associated virus.WO9506743 (1995).
38. Amalfitano, A., Koeberl, D.D., Sun, B. Viral vectors and methods for producing and using the same. US20050220766 (2005).
39. Wilson, J.M., Xiao, W. Methods and vector constructs useful for production of recombinant AAV. US003073232. (2003).
40. Grimm D, Kern A, Rittner K, Kleinschmidt JA. Novel tools for production and purification of recombinant adenoassociated virus vectors. Hum Gene Ther 1998; 9(18): 2745-60.
41. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998; 72(3): 2224-32.
42. Wadsworth, S.C., Vincent, K., Piraino, S., Kyostio, S. Improved AAV vectors for gene therapy. EP1983057 (2008).
43. Atkinson, E.M., Wilkins, P.C., Fung, V.P., Takeya, R.K., Reynolds, T.C. Methods for generating high titer helper free preparations of recombinant AAV vectors. EP2325299 (1998).
44. Atkinson, E.M., Wilkins, P.C., Fung, V.P., Takeya, R.K., Reynolds, T.C. Methods for generating high titer helper free preparations of recombinant AAV vectors. US2010248355 (2010).
45. Conway JE, Rhys CM, Zolotukhin I, Zolotukhin S, Muzyczka N, Hayward GS, et al. High-titer recombinant adeno-associated virus production utilizing a recombinant herpes simplex virus type I vector expressing AAV-2 Rep and Cap. Gene Ther 1999; 6(6): 986-93.
46. Booth MJ, Mistry A, Li X, Thrasher A, Coffin RS. Transfectionfree and scalable recombinant AAV vector production using HSV/AAV hybrids. Gene Ther 2004; 11(10): 829-37.
47. Hwang, KK, Mandell T, Kinter H, Zolotukhin S, Snyder R, Byrne BJ. High titer of recombinant adeno-associated virus production using replication deficient herpes simplex viruses type 1. Mol Ther 2003; 7: S14-S15
48. Hwang, K.K. High titer recombinant AAV production. WO2004027048 (2004).
49. Zolotukhin, S., Muzyczka, N., Hayward, G.S., Conway, J.E., Birne, B.J. Methods for large-scale production of recombinant AAV vectors. AU2004218673 (2004).
50. Hwang, K.K., Knop, D. Recombinant AAV production in mammalian cells. WO2008021140 (2008).
51. Coffin, R.S., Booth, M.J. Adeno-associated virus producer systems. US2005226847 (2005).
52. Knop, D., Thomas, D., Veres, G. Recombinant virus production using mammalian cells in suspension. US2008227138 (2008).
53. Urabe M, Ding C, Kotin RM. Insect cells as a factory to produce Adeno-associated virus type 2 vectors. Hum Gene Ther 2002; 13(16): 1935-43.
54. Negrete A, Yang LC, Mendez AF, Levy JR, Kotin RM. Economized large-scale production of high yield of rAAV for gene therapy applications exploiting baculovirus expression system. J Gene Med 2007; 9(11): 938-48.
55. Kotin, R.M., Urabe, M., Ding, C.T. Packaging lines for generation of high titers of recombinant AAV vectors. US2004197895 (2004).
56. Urabe, M. Improved AAV vectors produced in insect cells. EP2311697 (2006).
57. Zolotukhin, S., Muzyczka, N. A modified baculovirus expression system for production of pseudotyped RAAV vector. WO2005072364 (2005).
58. Aslanidi G, Lamb K, Zolotukhin S. An inducible system for highly efficient production of recombinant adeno-associated virus (rAAV) vectors in insect Sf9 cells. Proc Natl Acad Sci USA 2009; 106(13): 5059-64.
59. Zolotukhin, S., Aslanidi, J. An inducible system for highly efficient production of recombinant adeno-associated virus (RAAV) vectors. WO2010114948 (2010).
60. Lubelsky, J., Noordman, Y., Bakker, A.C., Monomeric AAV vectors. WO2011122950 (2011).
61. Vandenberghe, L., Wilson, J.M., Lock, M. Scalable production methods for AAV.WO2007127264 (2007).
62. Snyder, R.O., Zolotukhin, S., Sakal, Y., Byrne, B.J., Zolotukhin, I., Loiler, S., Potter, M.R., Chiodi, V.A., Muzyczka, N., Hauswirth, W., Flotte, T.R., Burger, C. Production of pseudotyped recombinant AAV virions. WO03104413 (2003).
63. Sheldon, P., Gagnon, P.S., Nichols, G., Thorne, B.A. Improved methods for purification of recombinant AAV vector. WO2010148143 (2010).
64. Wright, J.F., Qu, G. Composition and methods to prevent AAV vector aggregation. US2011076744 (2011).
65. Heilbronn, R. Identification and characterization of recombinant viral gene therapy vectors. WO2010031865 (2010).
66. Blixt O, Head S, Mondala T, Scanlan C, Huflejt ME, Alvarez R, et al. Printed covalent glycan array for ligand profiling of diverse glycan binding proteins. Proc Natl Acad Sci USA 2004; 101(49): 17033-8.
67. Sun, L., Juan, L., Xiao, X. Overcaming AAV vector limitations through viral DNA hetero dimerization. US2002076754 (2002).
68. Liu X, Luo M, Zhang LN, Lian Z, Zak R, Ding W, et al. Spliceosome-mediated RNA trans-splicing with recombinant adenoassociated virus partially restores cystic fibrosis transmembrane conductance regulator function to polarized human cystic fibrosis airway epithelial cells. Hum Gene Ther 2005; 16(9): 1116-23.
69. Yan Z, Zhang Y, Duan D, Engelhardt JF. Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy. Proc Natl Acad Sci U S A 2000; 97(12): 6716-21.
70. Reich SJ, Auricchio A, Hildinger M, Glover E, Maguire AM, Wilson JM, et al. Efficient trans-splicing in the retina expands the utility of adeno-associated virus as a vector for gene therapy. Hum Gene Ther 2003; 14(1): 37-44.
71. Samulski, R.J., McCarty, J.M. Duplexed parvovirus vectors. WO200192551 (2001), EP1626091 (2006) & US2010310516 (2010).
72. Carter, B.J. Enhancement of expression of a single-stranded heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms intrastrand base pair. EP1916258 (2008).
73. Wang Z, Ma HI, Li J, Sun L, Zhang J, Xiao X. Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther 2003; 10(26): 2105-11.
74. McCarty DM, Monahan PE, Samulski RJ. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther 2001; 8(16): 1248-54.
75. Wu Z, Asokan A, Samulski RJ. Adeno-associated virus serotypes: Vector toolkit for human gene therapy. Mol Ther 2006; 14(3): 316-27.
76. Kong F, Li W, Li X, Zheng Q, Dai X, Zhou X, et al. Selfcomplementary AAV5 vector facilitates quicker transgene expression in photoreceptor and retinal pigment epithelial cells of normal mouse. Exp Eye Res 2010; 90(5): 546-54.
77. Nam HJ, Lane MD, Padron E, Gurda B, McKenna R, Kohlbrenner E, et al. Structure of adeno-associated virus serotype 8, a gene therapy vector. J Virol 2007; 81(22): 12260-71.
78. Gao, G., Wilson, J.W., Alvira, M. Adeno-Associated virus (AAV) serotype 9 sequence, vectors, containing same and uses thereof. US2005014262 (2005).
79. Bish LT, Morine K, Sleeper MM, Sanmiguel J, Wu D, Gao G, et al. Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat. Hum Gene Ther 2008; 19(12): 1359-68.
80. Hauck B, Chen L, Xiao W. Generation and characterization of chimeric recombinant AAV vectors. Mol Ther 2003; 7(3): 419-25.
81. Girod A, Ried M, Wobus C, Lahm H, Leike K, Kleinschmidt J, et al. Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat Med 1999; 5(9): 1052-6.
82. Bartlett JS, Kleinschmidt J, Boucher RC, Samulski RJ. Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab'gamma)2 antibody. Nat Biotechnol 1999; 17(2): 181-6.
83. Bartlett, J.S., Stachler, M. AAV vector and methods. US2005287122 (2005).
84. Michelfelder S, Lee MK, deLima-Hahn E, Wilmes T, Kaul F, Müller O, et al. Vectors selected from adeno-associated viral display peptide libraries for leukemia cell-targeted cytotoxic gene therapy. Exp Hematol 2007; 35(12): 1766-76.
85. Kleinschmidt, J., Muller, O., Trepel, M., Kaul, F. Random peptide library displayed on AAV vectors. WO2004083441 (2004).
86. Kleinschmidt, J., Muller, O., Trepel, M., Kaul, F., Leder, C. Random peptide library displayed on AAV vectors. US2007172460 (2007).
87. Grifman M, Trepel M, Speece P, Gilbert LB, Arap W, Pasqualini R, et al. Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids. Mol Ther 2001; 3(6): 964-75.
88. Weitzman, M.D., Cathomen, A.J. Method of identifying cellular regulators of adeno-associated virus (AAV). US2002182595 (2002).
89. Perabo L, Endell J, King S, Lux K, Goldnau D, Hallek M, et al. Combinatorial engineering of a gene therapy vector: Directed evolution of adeno-associated virus. J Gene Med 2006; 8(2): 155-62.
90. Maheshri N, Koerber JT, Kaspar BK, Schaffer DV. Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat Biotechnol 2006; 24(2): 198-204.
91. Vega, M., Drittanti, L. High throughput directed evolution by rational mutagenesis. US20030134351 (2003).
92. Grimm D, Lee JS, Wang L, Desai T, Akache B, Storm TA, et al. In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J Virol 2008; 82(12): 5887-911.
93. Kay, M.A., Grimm, D. AAV capsid library and AAV capsid proteins. WO2007120542 (2007).
94. Kay, M., Grimm, D. Capsid library and AAV Capsid proteins. US2010047174 (2010).
95. Xiao, X., Yang, L. Directed evolution and in vivo panning of virus vector. US2011104120 (2011).
96. Li W, Asokan A, Wu Z, Van Dyke T, Di Primo N, Johnson JS, et al. Engineering and selection of shuffled AAV genomes: A new strategy for producing targeted biological nanoparticles. Mol Ther 2008; 16(7): 1252-60.
97. Yang L, Jiang J, Drouin LM, Agbandje-McKenna M, Chen C, Qiao C, et al. A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc Natl Acad Sci U S A 2009; 106(10): 3946-51.
98. Bowles, D.E., Li, C., Rabinowitz, J.E., Grieger, J., Agbandje-Mc Kenna, M., Samulski, R.J. Chimeric vectors. US2011104119 (2011).
99. Gray SJ, Blake BL, Criswell HE, Nicolson SC, Samulski RJ, McCown TJ. Direct evolution of a novel adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Nat Med 2003; 9: 135-9.
100. McCown, T.J., Haberman, R.P. Secretion signal vectors. WO03093295 (2003).
101. Behrooz, S., Shah, P.K. Effective vector platform for gene transfer and gene therapy. WO2010141706 (2010).
102. Engelhardt, J., Dual, D. Adeno-associated virus vectors. US20050255087 (2005).
103. Moskalenko M, Chen L, van Roey M, Donahue BA, Snyder RO, McArthur JG, et al. Epitope mapping of human anti-adenoassociated virus type 2 neutralizing antibodies: Implications for gene therapy and virus structure. J Virol 2000; 74(4): 1761-6.
104. Erles K, Sebokova P, Schlehofer JR. Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J Med Virol 1999; 59(3): 406-11.
105. Scallan CD, Jiang H, Liu T, Patarroyo-White S, Sommer JM, Zhou S, et al. Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice. Blood 2006; 107(5): 1810-7.
106. Lochrie MA, Tatsuno GP, Christie B, McDonnell JW, Zhou S, Surosky R, et al. Mutations on the external surfaces of adenoassociated virus type 2 capsids that affect transduction and neutralization. J Virol 2006; 80(2): 821-34.
107. Huttner NA, Girod A, Perabo L, Edbauer D, Kleinschmidt JA, Büning H, et al. Genetic modifications of the adeno-associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies. Gene Ther 2003; 10(26): 2139-47.
108. Arbetman, A.E., Colosi, P.C., Lochrie, M.A., Surosky, R.T. AAV virions with decreased immunoreactivity and uses thereof. US2008008690 (2008).
109. Schaffer, D., Kaspar, B., Maheshri, N. Mutated Adeno-associated virus virions and methods of use thereof. US2009202490 (2009).
110. Maguire AM, Simonelli F, Pierce EA, Pugh EN Jr, Mingozzi F, Bennicelli J, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 2008; 358(21): 2240-8.
111. Acland, G.M. Method of treating or retarding the development of blindness. WO2002082904 (2002).
112. Acland GM, Aguirre GD, Ray J, Zhang Q, Aleman TS, Cideciyan AV, et al. Gene therapy restores vision in a canine model of childhood blindness. Nat Genet 2001; 28(1): 92-5.
113. Jacobson SG, Aleman TS, Cideciyan AV, Zhang Q, Aleman TS, Cideciyan AV, et al. Identifying photoreceptors in blind eyes caused by RPE65 mutations: Prerequisite for human gene therapy success. Proc Natl Acad Sci USA 2005; 102(17): 6177-82.
114. Cideciyan AV, Hauswirth WW, Aleman TS, Kaushal S, Schwartz SB, Boye SL, et al. Vision 1 year after gene therapy for Leber's congenital amaurosis. N Engl J Med 2009; 361(7): 725-7.
115. Simonelli F, Maguire AM, Testa F, Pierce EA, Mingozzi F, Bennicelli, JL, et al. Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther 2010; 18(3): 643-50.
116. Maguire AM, High KA, Auricchio A, Wright JF, Pierce EA, Testa F, et al. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: A phase 1 dose-escalation trial. Lancet 2009; 374(9701): 1597-605.
117. Hauswirth WW, Aleman TS, Kaushal S, Cideciyan AV, Schwartz SB, Wang L, et al. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: Short-term results of a phase I trial. Hum Gene Ther 2008; 19(10): 979-90.
118. Maclachlan TK, Lukason M, Collins M, Munger R, Isenberger E, Rogers C, et al. Preclinical safety evaluation of AAV2-sFLT01- a gene therapy for age-related macular degeneration. Mol Ther 2011; 19(2): 326-34
119. Scaria, A., Pechan, P., Wadsworth, S. Multimeric constructs. WO2006031689 (2006).
120. Wilson, G. Vandenberghe, N.H., Bennett, J., Kozarsky K., Ertl, P. AAV7 viral vectors for targeted delivery of RPE cells. WO2009134681 (2009).
121. Barkatet, M. Widespread gene delivery to the retina using systemic administration of AAV vectors. EP2287323 (2009).
122. Eberling JL, Jagust WJ, Christine CW, Starr P, Larson P, Bankiewicz KS, et al. Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 2008; 70(21): 1980-3.
123. Ozawa, K., Fujimoto, K.I., Muramatsu, S.I., Ikeguchi, K., Nakano, I. Methods of treating Parkinson's disease using recombinant adeno-asociated virus virions. US20020172664 (2002).
124. Muramatsu S, Fujimoto K, Kato S, Mizukami H, Asari S, Ikeguchi K, et al. A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease. Mol Ther 2010; 18(9): 1731-5.
125. LeWitt PA, Rezai AR, Ojemann SG, Flaherty AW, Eskandar EN, Leehey MA, et al. AAV2-GAD gene therapy for advanced Parkinson's disease: A double-blind, sham-surgery controlled, randomised trial. Lancet Neurol 2011; 10(4): 309-19.
126. During, M., Kaplitt, M. Glutamiv acid decarboxylase based delivery systems. US20050025746 (2005).
127. Musatov, S. Novel gene therapy approach for treating the metabolic disorder obesity. WO2009058970 (2009) & US20090110661 (2009).
128. Kells AP, Hadaczek P, Yin D, Bringas J, Varenika V, Forsayeth J,et al. Efficient gene therapy-based method for the delivery of therapeutics to primate cortex. Proc Natl Acad Sci USA 2009; 106(7): 2407-11.
129. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 1994; 91(6): 2076-80.
130. Liu G, Martins I, Wemmie JA, Chiorini JA, Davidson BL. Functional correction of CNS phenotypes in a lysosomal storage disease model using adeno-associated virus type 4 vectors. J Neurosci 2005; 25(41): 9321-7.
131. Bankiewicz, K.S., Administration of growth factors for the treatment of CNS disorders. US20070254842 (2007).
132. Marks WJ, Jr., Bartus RT, Siffert J, Davis CS, Lozano A, Boulis N, et al. Gene delivery of AAV2-neurturin for Parkinson's disease: A double-blind, randomised, controlled trial. Lancet Neurol 2010; 9(12): 1164-72.
133. McPhee SW, Janson CG, Li C, Samulski RJ, Camp AS, Francis J, et al. Immune responses to AAV in a phase I study for Canavan disease. J Gene Med 2006; 8(5): 577-88.
134. Leone, P., During, M.J., Sorgi, F.L. Delivery system for gene therapy to the brain.WO199846273 (1998).
135. Dodge, J., Cheng, S. H. Gene therapy for lysosomal storage diseases. WO2008154198 (2008).
136. Worgall S, Sondhi D, Hackett NR, Kosofsky B, Kekatpure MV, Neyzi N, et al. Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Hum Gene Ther 2008; 19(5): 463-74.
137. Passini, M., Shewsbury, M.A., Gene therapy for neurometabolic disorders. EP2269658 (2005).
138. Passini, M., Stewart, G.R. Gene therapy for neurometabolic disorders. WO2005120581 (2005).
139. Wang, L., Muramatsu, S.I, Nakano, I., Mizukami, H., Ozawa, K. Adeno-associated virus mediated delivery of GDNF to skeletal muscle. US20030161814 (2003).
140. Kaspar, B.K., Gage, F.H., Rothstein, J.D. Targeted retrograde gene delivery to motor neurons. US20070003524 (2007).
141. Fu H, Dirosario J, Killedar S, Zaraspe K, McCarty DM. Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery. Mol Ther 2011; 19(6): 1025-33.
142. Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 2009; 27(1): 59-65.
143. Rafael JA, Cox GA, Corrado K, Jung D, Campbell KP, Chamberlain JS. Forced expression of dystrophin deletion constructs reveals structure-function correlations. J Cell Biol 1996; 134(1): 93-102.
144. Crawford GE, Faulkner JA, Crosbie RH, Campbell KP, Froehner SC, Chamberlain JS. Assembly of the dystrophin-associated protein complex does not require the dystrophin COOH-terminal domain. J Cell Biol 2000; 150(6): 1399-410.
145. Wang B, Li J, Xiao X. Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc Natl Acad Sci USA 2000; 97(25): 13714-9.
146. Wang B, Li J, Fu FH, Xiao X. Systemic human minidystrophin gene transfer improves functions and life span of dystrophin and dystrophin/utrophin-deficient mice. J Orthop Res 2009; 27(4): 421-6.
147. Watchko J, O'Day T, Wang B, Zhou L, Tang Y, Li J, Xiao X. Adeno-associated virus vector-mediated minidystrophin gene therapy improves dystrophic muscle contractile function in mdx mice. Hum Gene Ther 2002; 13(12): 1451-60.
148. Wang B, Li J, Qiao C, Chen C, Hu P, Zhu X, Zhou L, et al. A canine minidystrophin is functional and therapeutic in mdx mice. Gene Ther 2008; 15(15): 1099-106.
149. Xiao, X. DNA sequences encoding dystrophin minigenes and methods of use thereof. US2006073586 (2006).
150. Stedman, H. Stable protection from dystrophic sarcolemmal degeneration and restoration of the sarcoglycan complex. WO1999043360 (1999).
151. Tang Y, Cummins J, Huard J, Wang B. AAV-directed muscular dystrophy gene therapy. Expert Opin Biol Ther 2010; 10(3): 395-408.
152. Mendell JR, Rodino-Klapac LR, Rosales-Quintero X, Kota J, Coley BD, Galloway G, et al. Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins. Ann Neurol 2009; 66(3): 290-7.
153. Mendell JR, Campbell K, Rodino-Klapac L, Sahenk Z, Shilling C, Lewis S, et al. Dystrophin immunity in Duchenne's muscular dystrophy. N Engl J Med 2010; 363(15): 1429-37.
154. Denti MA, Rosa A, D'Antona G, Sthandier O, De Angelis FG, Nicoletti C, et al. Body-wide gene therapy of Duchenne muscular dystrophy in the mdx mouse model. Proc Natl Acad Sci USA 2006; 103(10): 3758-63.
155. Goyenvalle A, Vulin A, Fougerousse F, Leturcq F, Kaplan JC, Garcia L, et al. Rescue of dystrophic muscle through U7 snRNAmediated exon skipping. Science 2004; 306(5702): 1796-9.
156. Ferlini, A., Medici, A., Perone, D., Rimessi, P., Spitali, P. Antisense oligo nucleotide capable of inducing exon skipping and the use thereof as a medicament for the treatment of Duchenne Muscular Dystrophy. WO2010150231 (2010).
157. Collard, J., Sherman Khorkova, O. Treatment of dystrophyn family related diseases by inhibition of natural antisense transcript to DMD family. WO2010129861 (2010).
158. Voit, T., Garcia, L., Robin, V., Dreyfus, P. Exon skipping therapy for functional amelioration of semifunctional dystrophin in Becker and Duchenne muscular dystrophy WO2011024077 (2011)
159. Hoffman BE, Dobrzynski E, Wang L, Hirao L, Mingozzi F, Cao O, et al. Muscle as a target for supplementary factor IX gene transfer. Hum Gene Ther 2007; 18(7): 603-13.
160. Podsakoff, G.M., Kessler, P.D., Byrne, B.J., Kurtzman, G.J. Adeno-associated viral vectors comprising a gene encoding a lysosomal enzyme. US005962313 (1999).
161. Podsakoff, G.M. Methods for delivering DNA to muscle cells using recombinant adeno-associated virus virion. EP1927660 (2008).
162. Hayden, M.R., Kastelein, J.P. LPL Variant therapeutics. WO200100220 (2001).
163. Stroes ES, Nierman MC, Meulenberg JJ, Franssen R, Twisk J, Henny CP, et al. Intramuscular administration of AAV1- lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase
164. Brantly ML, Chulay JD, Wang L, Mueller C, Humphries M, Spencer LT, et al. Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc Natl Acad Sci USA 2009; 106(38): 16363-8.
165. Leiden, J.M., Svensson, E. Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors. US7078387 (2006).
166. Hajjar, R.J., Lompr, A.M., Lipskaia, L., Del Monte, F. Methods of treating restenosis. US7291604 (2007)
167. Jaski BE, Jessup ML, Mancini DM, Cappola TP, Pauly DF, Greenberg B, et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. J Card Fail 2009; 15(3): 171-81.
168. Flotte, T.R., Sirninger, J.R., Guggino, W.B., Cebotaru, L., Muller, C. Composition and methods for treating cystic fibrosis. US2008003204 (2008).
169. Wagner JA, Nepomuceno IB, Messner AH, Moran ML, Batson EP, Dimiceli S, et al. A phase II, double-blind, randomized, placebocontrolled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies. Hum Gene Ther 2002; 13(11): 1349-59.
170. Shi, G.Y., Wu, H.L., Lin, C.N., Lin, S.W. Recombinant factor IX and use thereof. EP2368983 (2008).
171. Manno CS, Chew AJ, Hutchison S, Larson PJ, Herzog RW, Arruda VR, et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 2003; 101(8): 2963-72.
172. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ, et al. Successful transduction of liver in hemophilia by AAVFactor IX and limitations imposed by the host immune response. Nat Med 2006; 12(3): 342-7.
173. High, K.A., Herzog, R.W. Methods and compositions for use in gene therapy for treatment of hemophilia. WO1998041240 (1998).
174. Couto L.B., Colosi P.C., Quian, X. Adeno-associated vector composition for expression of factor VIII. US20050276787 (2005).
175. Podsakoff, G.M., Watson, G. Recombinant adeno-associated virus virions for the treatment of lysosomal disorders. US6582692 (2003).
176. Kurtzman, G.J., Colosi, P.C. Gene therapy for thetreatment of solid tumors using recombinant adeno-associated virus vectors. US6531456 (2003).
177. Fang, J., Jooss, K. AAV vector composition and methods for enhanced expression of immunoglobulins using the same. US20060034805 (2006).
178. Anklesaria, P. Methods for treating target joints in inflammatory arthritis using AAV vectors encoding a TNF antagonist. WO2008175845 (2008).
179. Mease PJ, Wei N, Fudman EJ, Kivitz AJ, Schechtman J, Trapp RG, et al. Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adeno-associated vector containing a tumor necrosis factor antagonist gene: results of a phase 1/2 Study. J Rheumatol 2010; 37(4): 692-703.
180. Mingozzi F, High KA. Immune responses to AAV in clinical trials. Curr Gene Ther 2011; 11(4): 321-30.
181. Mingozzi F, Maus MV, Hui DJ, Sabatino DE, Murphy SL, Rasko JE, et al. CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med 2007; 13(4): 419-22.
182. Calcedo R, Vandenberghe LH, Gao G, Lin J, Wilson JM. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis 2009; 199(3): 381-90.
183. Pien GC, Basner-Tschakarjan E, Hui DJ, Mentlik AN, Finn JD, Hasbrouck NC, et al. Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors. J Clin Invest 2009; 119(6): 1688-95.
184. Vandenberghe LH, Wang L, Somanathan S, Zhi Y, Figueredo J, Calcedo R, et al. Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid. Nat Med 2006; 12(8): 967-71.
185. Basner-Tschakarjan E, Mingozzi F, Chen Y, Nathwani AC, Tuddenham EGD, Rosales C, et al. Dose-dependent activation of capsid-specific T cells after AAV serotype 8 vector administration in a clinical study for hemophilia. Mol Ther 2011; 19 (suppl. 2): s230.
186. Finn JD, Hui D, Downey HD, Dunn D, Pien GC, Mingozzi F, et al. Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transduction. Mol Ther 2009; 18(1): 135-42.
187. Poulsen, D., Von Doersten, P., Lurie, D., Stone, I. AAV mediated gene delivery to cochlear cells. US20050281786 (2005).
188. Chiorini, J.A., Schmidt, M., Bossis, I., Di Pasquale, G. Bovine adeno-associated viral vector and uses therefore. WO2005056807 (2005).
189. Kilpatrick LA, Li Q, Yang J, Goddard JC, Fekete DM, Lang H. Adeno-associated virus-mediated gene delivery into the scala media of the normal and deafened adult mouse ear. Gene Ther 2011; 18(6): 569-78.
190. Ortolano S, Di Pasquale G, Crispino G, Anselmi F, Mammano F, Chiorini JA. Coordinated control of connexin 26 and connexin 30 at the regulatory and functional level in the inner ear. Proc Natl Acad Sci U S A 2008; 105(48): 18776-81.
191. Crispino G, Di Pasquale G, Scimemi P, Rodriguez L, Galindo Ramirez F, De Siati RD, et al. BAAV mediated GJB2 gene transfer restores gap junction coupling in cochlear organotypic cultures from deaf Cx26Sox10Cre mice. PLoS One 2011; 6(8): e23279.
192. Urnov FD, Rebar EJ, Holmes MC, Zhang HS, Gregory PD. Genome editing with engineered zinc finger nucleases. Nat Rev Genet 2010; 11(9): 636-46.
193. Miller, J.C. Engineered cleavage half-domains. US20090311787 (2009).
194. Zhang H.S., Gregory, P.D. Anti angiogenic methods and composition. US20080187523 (2008).